Cardiac involvement in Fabry's disease

Heart Lung and Circulation

Volumn 14, Issue SUPPL. 2, 2005, Pages

  Nicholls, Kathy ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA;

ADULT; AGE; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; GENDER; GOVERNMENT; HEALTH CARE COST; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE BIOPSY; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RESOURCE ALLOCATION; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH; SURVIVAL TIME; SYMPTOMATOLOGY;

EID: 30344447675     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2005.09.007     Document Type: Article

References (2)

1. Galanos J, Nicholls K, Grigg L, Kiers L, Crawford A, Becker G. Clinical features of Fabry's disease in Australian patients. Int Med J 2002;32:575-84.
2. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase. A replacement therapy in Fabry's disease. N Eng J Med 2001;345(1):9-16.